Cholesterol esterification inhibition suppresses prostate cancer metastasis by impairing the Wnt/β-catenin pathway

HJ Lee, J Li, RE Vickman, J Li, R Liu, AC Durkes… - Molecular Cancer …, 2018 - AACR
HJ Lee, J Li, RE Vickman, J Li, R Liu, AC Durkes, BD Elzey, S Yue, X Liu, TL Ratliff…
Molecular Cancer Research, 2018AACR
Dysregulation of cholesterol is a common characteristic of human cancers including prostate
cancer. This study observed an aberrant accumulation of cholesteryl ester in metastatic
lesions using Raman spectroscopic analysis of lipid droplets in human prostate cancer
patient tissues. Inhibition of cholesterol esterification in prostate cancer cells significantly
suppresses the development and growth of metastatic cancer lesions in both orthotopic and
intracardiac injection mouse models. Gene expression profiling reveals that cholesteryl ester …
Abstract
Dysregulation of cholesterol is a common characteristic of human cancers including prostate cancer. This study observed an aberrant accumulation of cholesteryl ester in metastatic lesions using Raman spectroscopic analysis of lipid droplets in human prostate cancer patient tissues. Inhibition of cholesterol esterification in prostate cancer cells significantly suppresses the development and growth of metastatic cancer lesions in both orthotopic and intracardiac injection mouse models. Gene expression profiling reveals that cholesteryl ester depletion suppresses the metastatic potential through upregulation of multiple regulators that negatively impact metastasis. In addition, Wnt/β-catenin, a vital pathway for metastasis, is downregulated upon cholesteryl ester depletion. Mechanistically, inhibition of cholesterol esterification significantly blocks secretion of Wnt3a through reduction of monounsaturated fatty acid levels, which limits Wnt3a acylation. These results collectively validate cholesterol esterification as a novel metabolic target for treating metastatic prostate cancer. Mol Cancer Res; 16(6); 974–85. ©2018 AACR.
AACR